Sterling Investment Counsel’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.33M Buy
9,241
+431
+5% +$92.7K 0.55% 29
2026
Q1
$1.92M Buy
8,810
+127
+1% +$28.2K 0.54% 35
2025
Q4
$1.91M Buy
8,683
+1,271
+17% +$290K 0.55% 32
2025
Q3
$1.72M Buy
7,412
+4,167
+128% +$849K 0.55% 35
2025
Q2
$602K Sell
3,245
-5,006
-61% -$930K 0.35% 50
2025
Q1
$1.73M Buy
8,251
+4,681
+131% +$910K 0.59% 32
2024
Q4
$634K Sell
3,570
-4,752
-57% -$874K 0.42% 40
2024
Q3
$1.64M Buy
8,322
+1,087
+15% +$203K 0.59% 32
2024
Q2
$1.24M Buy
7,235
+443
+7% +$73.4K 0.49% 38
2024
Q1
$1.24M Buy
6,792
+490
+8% +$84.4K 0.57% 37
2023
Q4
$977K Buy
6,302
+1,436
+30% +$209K 0.5% 40
2023
Q3
$725K Buy
4,866
+890
+22% +$131K 0.42% 49
2023
Q2
$536K Sell
3,976
-279
-7% -$40.9K 0.29% 61
2023
Q1
$678K Buy
4,255
+1,499
+54% +$229K 0.4% 44
2022
Q4
$445K Buy
2,756
+103
+4% +$15.8K 0.28% 70
2022
Q3
$356K Buy
2,653
+387
+17% +$55.5K 0.26% 76
2022
Q2
$347K Buy
2,266
+602
+36% +$92K 0.26% 94
2022
Q1
$270K Buy
1,664
+187
+13% +$27.2K 0.18% 117
2021
Q4
$200K Buy
+1,477
New +$174K 0.14% 138

Other funds holding ABBV

Sterling Investment Counsel's ABBV Position: Q2 2026 in Review

Sterling Investment Counsel increased its AbbVie (ABBV) stake by 4.9% in Q2 2026, buying an estimated $92.7K and bringing the position to 9,241 shares worth $2.33M. The position accounts for 0.55% of the portfolio, ranked #29.

Sterling Investment Counsel first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sterling Investment Counsel held 9,241 shares of AbbVie worth $2.33M as of Q2 2026.
  • Sterling Investment Counsel bought 431 AbbVie shares in Q2 2026, an estimated $92.7K.
  • AbbVie made up 0.55% of Sterling Investment Counsel's portfolio in Q2 2026, its #29 holding.
  • Sterling Investment Counsel first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sterling Investment Counsel's 13F filing for Q2 2026, filed 20 Jul 2026.